Déjà disponible à l’hôpital depuis 2016, ENTRESTO comprimé pelliculé, association fixe de sacubitril et de valsartan, peut désormais être délivré en pharmacie de ville. Compare Enalapril vs. Valsartan, which is better for uses like: High Blood Pressure, Chronic Heart Failure and Heart Failure. Compare head-to-head ratings, side effects, warnings, dosages, interactions and patient reviews. Patients rated Enalapril 3.3/5 over Valsartan 2.9/5 in overall satisfaction. Study Design. Eligible patients were randomized in a 1:1 fashion to sacubitril/valsartan (n = 440) or enalapril (n = 441). Initial dose of sacubitril/valsartan was 24/26 or 49/51 mg, and for enalapril was 2.5 or 5 mg, both given orally twice daily. A sacubitril-valsartan therapy regimen was associated with greater reductions in NT-proBNP concentrations in patients with HFrEF compared with enalapril. Enalapril is a good blood pressure-lowering medicine that protects kidney function. Diovan (Valsartan) is a good blood pressure-lowering medicine that protects kidney function like an ACE inhibitor, but with fewer side effects. Original Article from The New England Journal of Medicine — Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure NEJM Group. (AHU377) and the ARB valsartan, was designed to. Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode. (PIONEER-HF) Patients are randomly assigned 1:1 to in-hospital initiation of sacubitril/valsartan titrated to 97/103 mg by mouth twice daily versus enalapril titrated to 10 mg by mouth twice daily for 8 weeks. All patients receive open-label treatment with sacubitril/valsartan for the remaining 4 weeks of the study. The primary efficacy end point is the time-averaged proportional change in amino terminal. Valsartan is similarly efficacious and safe to enalapril in patients with stable, mild/moderate heart failure, previously stabilised on an angiotensin-converting enzyme inhibitor and directly switched to study medication. ENTRESTO comprimé pelliculé est une nouvelle association fixe de sacubitril, premier représentant de la nouvelle classe des inhibiteurs de la néprilysine, et de valsartan, un antagoniste des récepteurs de l'angiotensine II.